tetano
Editor, Senior Moderator
J Chin Med Assoc. 2020 Apr 1. doi: 10.1097/JCMA.0000000000000318. [Epub ahead of print]
Potential therapeutic agents against COVID-19: What we know so far.
Lu CC[SUP]1[/SUP], Chen MY[SUP]1[/SUP], Chang YL[SUP]1,[/SUP][SUP]2[/SUP].
Author information
Abstract
The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread all over the world. Agents or vaccines of proven efficacy to treat or prevent human coronavirus infection are in urgent need and are being investigated vigorously worldwide. This review summarizes the current evidence of potential therapeutic agents, such as lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, hydroxychloroquine, interferon, ribavirin, tocilizumab and sarilumab. More clinical trials are being conducted for further confirmation of the efficacy and safety of these agents in treating COVID-19.
PMID:32243270DOI:10.1097/JCMA.0000000000000318
Potential therapeutic agents against COVID-19: What we know so far.
Lu CC[SUP]1[/SUP], Chen MY[SUP]1[/SUP], Chang YL[SUP]1,[/SUP][SUP]2[/SUP].
Author information
Abstract
The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread all over the world. Agents or vaccines of proven efficacy to treat or prevent human coronavirus infection are in urgent need and are being investigated vigorously worldwide. This review summarizes the current evidence of potential therapeutic agents, such as lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, hydroxychloroquine, interferon, ribavirin, tocilizumab and sarilumab. More clinical trials are being conducted for further confirmation of the efficacy and safety of these agents in treating COVID-19.
PMID:32243270DOI:10.1097/JCMA.0000000000000318